Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 250

    1.

    Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

    Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N.

    Blood. 2012 Mar 15;119(11):2568-78. Epub 2012 Jan 31.

    PMID:
    22294726
    [PubMed - indexed for MEDLINE]
    2.

    Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.

    Guilloton F, Caron G, Ménard C, Pangault C, Amé-Thomas P, Dulong J, De Vos J, Rossille D, Henry C, Lamy T, Fouquet O, Fest T, Tarte K.

    Blood. 2012 Mar 15;119(11):2556-67. Epub 2012 Jan 30.

    PMID:
    22289889
    [PubMed - indexed for MEDLINE]
    3.

    How I treat enteropathy-associated T-cell lymphoma.

    Di Sabatino A, Biagi F, Gobbi PG, Corazza GR.

    Blood. 2012 Mar 15;119(11):2458-68. Epub 2012 Jan 23.

    PMID:
    22271451
    [PubMed - indexed for MEDLINE]
    4.

    Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

    Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH.

    Blood. 2012 Apr 19;119(16):3767-78. Epub 2012 Jan 23.

    PMID:
    22271448
    [PubMed - in process]
    6.

    Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

    Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery S, Woessmann W, Schwänen C, Trümper L, Wessendorf S, Spang R, Hasenclever D, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.

    Blood. 2012 Feb 23;119(8):1882-7. Epub 2012 Jan 11.

    PMID:
    22238326
    [PubMed - indexed for MEDLINE]
    7.

    Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.

    Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW.

    Blood. 2012 Mar 1;119(9):2056-65. Epub 2012 Jan 10.

    PMID:
    22234700
    [PubMed - indexed for MEDLINE]
    8.

    T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.

    Sabbah S, Jagne YJ, Zuo J, de Silva T, Ahasan MM, Brander C, Rowland-Jones S, Flanagan KL, Hislop AD.

    Blood. 2012 Mar 1;119(9):2083-92. Epub 2012 Jan 10.

    PMID:
    22234686
    [PubMed - indexed for MEDLINE]
    9.

    Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

    Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U.

    Blood. 2012 Mar 1;119(9):2066-73. Epub 2012 Jan 10.

    PMID:
    22234681
    [PubMed - indexed for MEDLINE]
    10.

    Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

    LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW.

    Blood. 2012 Mar 1;119(9):2093-9. Epub 2012 Jan 10.

    PMID:
    22234679
    [PubMed - indexed for MEDLINE]
    11.

    Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

    Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L.

    Blood. 2012 Mar 8;119(10):2228-33. Epub 2012 Jan 5.

    PMID:
    22223822
    [PubMed - indexed for MEDLINE]
    12.

    IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

    Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, Mak TW.

    Blood. 2012 Feb 23;119(8):1901-3. Epub 2012 Jan 3.

    PMID:
    22215888
    [PubMed - indexed for MEDLINE]
    13.

    Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

    Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD.

    Blood. 2012 Mar 1;119(9):1963-71. Epub 2011 Dec 30.

    PMID:
    22210878
    [PubMed - indexed for MEDLINE]
    14.

    PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

    Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ.

    Blood. 2012 Feb 23;119(8):1897-900. Epub 2011 Dec 30.

    PMID:
    22210877
    [PubMed - indexed for MEDLINE]
    15.

    Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.

    O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L.

    Blood. 2012 Feb 16;119(7):1717-25. Epub 2011 Dec 20.

    PMID:
    22186993
    [PubMed - indexed for MEDLINE]
    16.

    Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

    Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, Horwitz S, Moskowitz AJ, Noy A, Palomba L, Perales MA, Portlock C, Straus D, Maragulia JC, Schoder H, Yahalom J.

    Blood. 2012 Feb 16;119(7):1665-70. Epub 2011 Dec 19.

    PMID:
    22184409
    [PubMed - indexed for MEDLINE]
    17.

    Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

    Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, Grogan TM, Teruya-Feldstein J, Rimsza LM.

    Blood. 2012 Feb 9;119(6):1459-67. Epub 2011 Dec 13.

    PMID:
    22167754
    [PubMed - indexed for MEDLINE]
    18.

    Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

    Ghosh SK, Perrine SP, Williams RM, Faller DV.

    Blood. 2012 Jan 26;119(4):1008-17. Epub 2011 Dec 7.

    PMID:
    22160379
    [PubMed - indexed for MEDLINE]
    19.

    Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009.

    Sjöberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, Björkholm M.

    Blood. 2012 Jan 26;119(4):990-6. Epub 2011 Dec 6.

    PMID:
    22147892
    [PubMed - indexed for MEDLINE]
    20.

    FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma.

    Ma YP, van Leeuwen FE, Cooke R, Broeks A, Enciso-Mora V, Olver B, Lloyd A, Broderick P, Russell NS, Janus C, Ashworth A, Houlston RS, Swerdlow AJ.

    Blood. 2012 Jan 26;119(4):1029-31. Epub 2011 Dec 5.

    PMID:
    22144180
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk